← Back to headlines
Zymeworks to Acquire Theravance Biopharma for $929 Million
Zymeworks has reached an agreement to acquire Theravance Biopharma in a deal valued at $929 million, marking a significant merger in the biopharmaceutical sector.
30 Jun, 08:26 — 30 Jun, 08:26
Sources
Showing 1 of 1 sources
